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Abstract 
Epidemiological  studies  on  cardiovascular  risk 
developed  many  assessment  models  which  are 
widely  available  for  the  public  use.  As  many 
arterial  occlusive  diseases  are  developed  from 
atherosclerosis  in  their  early  stage,  it  is 
meaningful to evaluate such models with respect 
to the clinical interpretation of atherosclerosis so 
as  to  promote  the  preventive  care  of  vascular 
diseases. Our study aims to make use of the data 
collection  form  from  the  Hong  Kong  Chinese 
type  II  diabetes  to  evaluate  and  compare  the 
performance  of  the  risk  assessment  models  of 
ARIC, FHS, UKPDS using ROC curve. 
We found that ARIC’s Stroke model gives the 
best performance whose AUC is 0.646 in model 
for Black. UKPDS’s Stroke has the lowest AUC, 
0.497.  It  was  found  that  ARIC  model  for  the 
Black Americans has superior performance with 




Type II diabetes leads to elevated glucose level 
and  can  be  complicated  to  various  vascular 
occlusive diseases, such as atherosclerosis. Since 
the  atherosclerosis  is  the  early  stage  of 
cardiovascular diseases (CVD), the identification 
of  atherosclerosis  can  predict  CVD  and  thus 
facilitate  preventive  care  of  CVD.  Although 
there exist many risk assessment models derived 
from clinical researches, the models can provide 
the risk of CVD only but not necessarily indicate 
the  relationship  with  the  diagnosis  of 
atherosclerosis. It is of significant contribution to 
evaluate  and  compare  the  performance  of  risk 
assessment  models  in  the  detection  of 
atherosclerosis. 
Cardiovascular  disease  (CVD),  a  group  of 
disorders in the heart and blood vessels, is the 
leading  cause  of  mortality  in  people  with 
diabetes,  including  coronary  heart  disease 
(CHD),  cerebrovascular  disease,  peripheral 
arterial disease, rheumatic heart disease, stroke, 
congenital  heart  disease  and  deep  vein 
thrombosis and pulmonary embolism. Although 
there  is  a  higher  prevalence  of  traditional  risk 
factors for CVD (i.e. hypertension, dyslipidemia, 
obesity) in persons with diabetes than in those 
without the disorder, these risk factors account 
for  less  than  half  of  the  mortality  from  CVD 
associated with diabetes
1. Thus, diabetes takes its 
place alongside the other major risk factors as a 
strong  independent  risk  factor  for  CVD. 
According  to  some  previous  research
1,2,3,4, 
individuals with diabetes have at least a twofold 
increased  risk  for  having  cardiovascular 
mortality  compared  with  age-matched  subjects 
without  diabetes
5.  Ischemic  heart  disease  and 
cerebrovascular  disease  are  listed  as  the 
important causes of morbidity and approximately 
65% of patients with diabetes die from CVD
3,6. 
As  the  serious  consequence  of  CVD  from 
diabetes  is  referred  above,  the  risk  assessment 
beneficial  to  type  2  diabetes  appears  to  be  of 
essential  significance.  It  will  have  widespread 
use  and  is  particularly  applied  for  health  care 
planners,  industry,  providers,  insurers  and 
government, as well as clinicians and patients, in 
order that optimal care can be determined. 
 
Risk models 
Many  long-term  prospective  studies  of  models 
for CVD risk have been reported such as ARIC 
(Atherosclerosis  Risk  in  Communities),  FHS 
(Framingham  Heart  Study),  UKPDS  (United 
Kingdom Prospective Diabetes Study). 
The FHS involved 5,209 adults widely aged 30 
to 62 at the time of the initial examination since 
1948.  Participants  followed  up  12  years,  and 
most  attended  the  11
th  examination  of  the 
original  Framingham  cohort,and  some  attended 
the  examination  of  the  Framingham  Offspring 
Study
9,10. Its risk factors include age, sex, SBP, 
DBP, Total-C, HDL-C, smoking, diabetes, ECG-
LVH  (left  ventricular  hypertrophy  by 
elecrocardiography),  alcohol  and  prevalent 
menopause  use  (for  women)
7,9.  And  a 
conventional  criterion  was  used  to  diagnose 
diabetes
13.  The  Weibull  regression  model  was 
applied to be statistical modeling in the study
8. UKPDS  recruited  5,102  patients  with  type  2 
diabetes from 25 to 65 years old, followed for a 
median of 10.7 years from 1977. It is a diabetes-
specific approach which is advantageous as it has 
HbA1c  as  a  continuous  variable.  The  UKPDS 
group replace age by age at diagnosis of diabetes 
and duration of diabetes as risk factors,besides 
sex, ethnicity, smoking, SysBP, Total-C, HDL-
C,  Atrial  fibrillation
11.  The  study  showed  that 
elevated LDL-C is the risk factor most predictive 
of future CV events
6. However, the study has the 
primary  limitation  that  the  cohort  in  the  study 
was  selected  for  a  clinical  trial,  so  it  is  not 
responsible for the general population
11. 
ARIC  was  derived  from  a  sizable  cohort  of 
15,792  middle-aged  persons  (45-64)  sampled 
from four US communities in 1987-1989. It is an 
engine for general population, with benefit from 
the remarkable progress in modern biochemistry. 
This  report  includes  follow-up  through  2000 
(midian, 12.3 years).It contains the risk factors: 
age,  sex,  race,  smoking,  Total-C,  HDL-C, 
SysBP,  medication  to  high  blood  pressure, 
diabetes.  The  study  group  used  Kaplan-Meier-
like  methods  to  calculate  the  relevant 
probabilities
15.  Unlike  the  former  study  of  the 
UKPDS,  in  which  the  authors  showed  that 
updated  mean  HbA1c  level  was  more  strongly 
related to increased risk of CVD compared with 
baseline  HbA1c  level
14,  the  ARIC  has  only  a 
single HbA1c measurement. The engine may not 
most  truly  reflect  long-term  glycemic  control, 
since  hemoglobin  A1c  is  an  inherently  time-
dependent  variable.  This  may  conclude  that 
ARIC is likely to underestimate the relationship 
between HbA1c level and CVD
15. 
However,these  models  above  can  not  early 
predict  CVD,as  they  provide  only  the 
consequence  of  the  occlusive  disease  such 
atherosclerosis. The previous models all mainly 
focus on the population of America and Europe, 
and  may  not  be  applied  to  other  populations, 
such as Chinese people in Asia. If we apply the 
model directly for Chinese people in Asia, the 
engine may not reflect the result truly because 
different  enthnic  has  differet  value  in 
fingures.(i.e. The mean of LDL in Finnish is 4.1, 
in Chinese is 2.5 mmol/l
16). 
We  have  not  find  any  risk  assessment  models 
which  can  predict  the  atherosclerosis  so  as  to 
support the preventive care of CVD , therefore 
this  study  is  aimed  to  make  use  of  the  data 
collection form from the pilot study to evaluate 
the performance of these risk assessment model 
using Receiver-Operating Characteristics (ROC) 
and compare the models based on the area under 




The  risk  assessment  models  were  evaluated 
using  the  data  collected  from  an  ongoing  pilot 
study  on  the  relationship  between  biomarker 
profile  and  hemodynamic  effect.  The  subject 
recruitment criteria of the pilot study are type II 
diabetes, age 46-60, Hong Kong Chinese, non-
smoking and without any records of stroke and 
chronic  coronary  heart  disease.  Thirty-two 
subjects (age: mean 54.2, SD 4.5; 10 males and 
22  females)  were  recruited.  With  the 
confirmation  by  a  radiologist,  the  ultrasound 
images showed the presence of atheromas at the 
common carotid artery, the internal carotid artery 
and the bifurcation of eight subjects. No carotid 




Each numerical risk factor is adjusted by adding 
the  difference  between  the  mean  of  that  risk 
factor in the corresponding CVD study, ms, and 
the mean of our collected data, mc. The mean-
corrected  value  of  risk  factor  xmc  is  calculated 
using the following formula. 
xmc=xc+ms-mc   
where xc is the collected datum of risk factor. 
 
Risk Assessment Models 
ARIC  study  provides  a  web-based  engine  for 
analyzing  the  CHD  and  stroke  risk  over  a  10-
year  period  based  on  a  number  of  risk  factors 
whose values can be entered through a graphical 
user  interface  in  the  web 
(http://www.aricnews.net/calculator.html).  Since 
this model considers the ethnic of black or white 
as one of the risk factors, two sets of the 10
th 
year’s  risk  values  were  generated  using  the 
collected data and assuming the ethnics are black 
and white respectively.  
FHS developed a scoring method
17,18,19 to evaluate 
the  10
th  year  risk  of  Hard  Coronary  Heart 
Disease(HCHD), CHD, and Stroke, and 2
nd year 
risk  of  CHD.  The  values  of  risk  factors  are 
stratified into various levels and mapped to the 
corresponding  points  through  lookup  tables. 
Adding all these points up results in a total score, 
which infers the 10-year risk through a lookup 
table. 
UKPDS  risk  engine  focuses  on  estimating  the 
risk of CVD in type II diabetes. The risk engine 
is  distributed  in  forms  of  application  software and  MS  Excel  spreadsheet  through  its  website 
(http://www.dtu.ox.ac.uk/riskengine/). 
Spreadsheet  was  used  to  estimate  the  risks  of 
fatal  and  non-fatal  stroke  and  CHD  because  it 
can facilitate batch processing of data using the 




We envisage the estimated risk as a predictor of 
carotid atherosclerosis. The gold standard is the 
radiologist’s  confirmation  of  the  carotid 
atherosclerosis plaques in the ultrasound images. 
The  risk  and  the  observation  were  checked 
against  each  other  and  the  Receiver-Operating 
Characteristics  (ROC)  curve  was  plotted  to 
illustrate the relationship between FPR (x-axis) 
and  TPR  (y-axis).  The  area  under  the  curve 
(AUC)  of  the  ROC  is  a  positive  real  number 
ranging  from  0  to  1,  which  indicates  the 
performance of the risk assessment model. For 
example,  if  the  AUC  is  0,  that  means  all 
predictions are false. If the AUC is 1, that means 
all predictions are true. If the AUC is 0.5, that 
means  the  predictions  are  randomly  generated. 
As a result, the risk assessment models can be 
said to be acceptable only if the AUC is between 
0.5  and  1.  Based  on  the  value  of  AUC,  the 
performance of the three risk assessment models 
can be compared. 
  


















Fatal and non-fatal 
CHD and Stroke 
10Y 
Age                
Age at 
Diagnosis 
        
     
    
Duration                     
BMI                     
Sex               
Ethnicity               
Total-C               
Smoker               
HDL-C               
Sys BP               
LDL-C                
Dis BP                
Diabetes                
Alcohol(women)                
Prevalent 
menopause use 
     
 
      
Medication                
Atrial 
Fibrillation 
     
   
   
HbA1c               
CVD               
LVH                
CHD                
 
Table 1  Overview of risk factors considered in the risk assessment models 
 
   
Result 
According to the methods above,we put the 32 
subjects’ data into each models and come to the 
AUC  in  Table 2 .  There  is  a  significantly 
different  AUC  among  the  3  models.  ARIC’s 
Stroke has the best evaluate performance which 
AUC is about 0.645833 in Black, 0.6409375 in 
White,  while  UKPDS’s  Stroke  has  the  lowest 
AUC which is around 0.5 (0.497396 for Stroke 
and 0.515625 for Fatal Stroke). As for the AUC 
of  FHS’s  CHD  and  Stroke  have  a  wide  rang 
from  0.510417  to  0.617188,  but  most  of  the 
indexes  are  mainly  around  0.55.  From  the 
average fingures of the 3 models AUC, we can 
see  the  the  models’  performance  directly.  We 
can conclude that ARIC has the best AUC (about 
0.6235),  and  UKPDS  has  the  worst  (about 
0.5358), which we can say ARIC is the best one 
among the 3 models to predict CVD in type II 




















Table 2  Comparison of the performance of the risk assessment models with respect to AUC of ROC 
 
Disscussion 
It has been argued that all patients with diabetes 
are at high or uncertain risk for CVD and deserve 
maximal  pharmacological  vascular  protection
16. 
Thus,  predictors,  which  may  warn  diabetic 
patients  with  hazard  ratio  appears  to  be  fairly 
important in the modern research. However, in 
the  three  models,  most  of  the  risk  factors  are 
conventional ones which can not keep pace with 
the  latest  update  in  the  mechanism  of 
atherosclerosis.  Novel  predominant  CVD  risk 
factors  are  needed  to  be  continually  revealed, 
which  may  benefit  the  risk  assessment  and 
prognosis  and  account  for  a  remarkable 
proportion of cardiovascular diseases in clinical 
practice. Furthermore, the risk equation in these 
models  is  out  of  flexibility.  It  may  not  be 
updated promptly or has to form a new equation 
to  keep  pace  with  the  discovery  of  novel  risk 
factors. In such case, the lack of flexibility may, 
in certain extent, prohibit the development of the 
prediction  models,  even  if  new  dominant  risk 
factor appears. 
This study evaluates the performance of ARIC, 
FHS  and  UKPDS  models  in  detecting  the 
atherosclerosis  in  Hong  Kong  Chinese  type  II 
diabetic patients. It was found that ARIC model 
for the Black Americans outperforms the other 
models with respect to a different cohort in Hong 
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